VYOLIA
DEAD

Serial Number

88867319

Owner

ALLERGAN SALES, LLC

Filing Date

Apr 10, 2020

Add to watchlist:

No watchlists yet
View on USPTO

VYOLIA Trademark

Serial Number: 88867319

VYOLIA is a trademark filed by ALLERGAN SALES, LLC on April 10, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

ALLERGAN SALES, LLC (490 trademarks)

5 GIRALDA FARMS
MADISON, NJ 07940

Entity Type: 16

Trademark Details

Filing Date

April 10, 2020

Registration Date

Not Registered

Published for Opposition

August 4, 2020

Goods & Services

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
May 2, 2022 MAB6
ABANDONMENT - NO USE STATEMENT FILED
May 2, 2022 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 10, 2021 EXRA
SOU EXTENSION 2 GRANTED
Aug 6, 2021 EX2G
SOU EXTENSION 2 FILED
Aug 6, 2021 EXT2
SOU TEAS EXTENSION RECEIVED
Aug 6, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 11, 2021 EXRA
SOU EXTENSION 1 GRANTED
Mar 9, 2021 EX1G
SOU EXTENSION 1 FILED
Mar 9, 2021 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 9, 2021 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 29, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 4, 2020 NPUB
PUBLISHED FOR OPPOSITION
Aug 4, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 15, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 29, 2020 CNSA
ASSIGNED TO EXAMINER
Jun 28, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 19, 2020 NWOS
NEW APPLICATION ENTERED
Apr 14, 2020 NWAP